Urogen Pharma Ltd

More Details of Urogen Pharma Ltd Company

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Company Info

Company codeURGN

Company nameUrogen Pharma Ltd

IPO dateMay 04, 2017

Founded at2004

CEOMs. Elizabeth A. (Liz) Barrett

Number of employees235

Security typeOrdinary Share

Fiscal year-endMay 04

Address9 Ha'ta'asiya St

CityRA'ANANA

Stock exchangeNASDAQ Global Market Consolidated

CountryIsrael

Postal code4365007

Phone97297707601

Websitehttps://www.urogen.com/

Company codeURGN

IPO dateMay 04, 2017

Founded at2004

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.94K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

32.51K

+28.89%

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Ms. Cynthia M. Butitta

Independent Director

--

Dr. Leana S. Wen, M.D.

Independent Director

--

Mr. Christopher Degnan

Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer

--

Mr. Vincent Perrone

Investor Relations

--

Mr. Daniel G. Wildman

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Arie S. Belldegrun, M.D.

Independent Chairman of the Board

408.69K

--

Ms. Elizabeth A. (Liz) Barrett

President, Chief Executive Officer, Director

326.94K

--

Mr. Jason Drew Smith

Chief Compliance Officer, General Counsel, Corporate Secretary

32.51K

+28.89%

Mr. James A. Robinson, Jr.

Independent Director

--

Dr. Mark P. Schoenberg, M.D.

Chief Medical Officer

--

Ms. Cynthia M. Butitta

Independent Director

--

Revenue Breakdown

Currency: USDUpdate time: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

By BusinessUSD

Name

Revenue

Proportion

Jelmyto

90.40M

0.00%

No Data

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

Jelmyto

90.40M

0.00%

Shareholder

Update time: 13 hours ago

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

RTW Investments L.P.

8.32%

RA Capital Management, LP

6.95%

UBS Asset Management (Switzerland)

5.73%

Menora Mivtachim Insurance Ltd.

4.99%

Vestal Point Capital, LP

4.67%

Other

69.34%

Shareholder Statistics

Shareholder

Proportion

RTW Investments L.P.

8.32%

RA Capital Management, LP

6.95%

UBS Asset Management (Switzerland)

5.73%

Menora Mivtachim Insurance Ltd.

4.99%

Vestal Point Capital, LP

4.67%

Other

69.34%

Type

Shareholder

Proportion

Investment Advisor

27.55%

Investment Advisor/Hedge Fund

24.49%

Hedge Fund

23.99%

Research Firm

8.75%

Insurance Company

6.73%

Venture Capital

3.28%

Corporation

2.97%

Bank and Trust

2.55%

Individual Investor

2.05%

Institutional Shareholding

Update time: Tue, Mar 4

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

278

43.89M

96.97%

-2.00M

2024Q4

280

43.94M

103.24%

-1.94M

2024Q3

262

44.13M

104.63%

-2.19M

2024Q2

247

46.02M

111.40%

+11.07M

2024Q1

255

34.96M

99.86%

+5.57M

2023Q4

237

29.16M

94.80%

+4.33M

2023Q3

238

25.93M

86.41%

+2.69M

2023Q2

222

19.52M

83.40%

-392.05K

2023Q1

221

19.00M

81.20%

-1.17M

2022Q4

218

18.34M

79.80%

-1.99M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

RTW Investments L.P.

3.83M

8.32%

+47.45K

+1.25%

Dec 31, 2024

UBS Asset Management (Switzerland)

1.36M

2.94%

+1.36M

--

Dec 31, 2024

Menora Mivtachim Insurance Ltd.

2.30M

5%

--

Mar 11, 2025

Vestal Point Capital, LP

1.63M

3.54%

+1.23M

+307.50%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

2.19M

4.76%

-23.39K

-1.06%

Dec 31, 2024

TD Securities, Inc.

1.75M

3.79%

+1.75M

--

Dec 31, 2024

Acorn Capital Advisors, LLC

1.52M

3.29%

+1.52M

--

Dec 31, 2024

Pontifax Venture Capital

1.49M

3.22%

-1.00

-0.00%

Mar 14, 2024

Related ETFs

Update time: Tue, May 6

Name

Proportion

ARK Israel Innovative Technology ETF

2.02%

ALPS Medical Breakthroughs ETF

0.38%

Amplify BlueStar Israel Technology ETF

0.36%

iShares Micro-Cap ETF

0.09%

ProShares Ultra Nasdaq Biotechnology

0.05%

Invesco Nasdaq Biotechnology ETF

0.05%

iShares Biotechnology ETF

0.04%

SPDR S&P International Small Cap ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

Global X Russell 2000 ETF

0.02%

ARK Israel Innovative Technology ETF

Proportion2.02%

ALPS Medical Breakthroughs ETF

Proportion0.38%

Amplify BlueStar Israel Technology ETF

Proportion0.36%

iShares Micro-Cap ETF

Proportion0.09%

ProShares Ultra Nasdaq Biotechnology

Proportion0.05%

Invesco Nasdaq Biotechnology ETF

Proportion0.05%

iShares Biotechnology ETF

Proportion0.04%

SPDR S&P International Small Cap ETF

Proportion0.03%

iShares Russell 2000 Growth ETF

Proportion0.02%

Global X Russell 2000 ETF

Proportion0.02%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

3.931USD